INDEMNIFICATION AGREEMENTIndemnification Agreement • October 22nd, 2021 • Synergy CHC Corp. • Medicinal chemicals & botanical products • Nevada
This Indemnification Agreement (the “Agreement”) is made and entered into as of , 2021 between Synergy CHC Corp., a Nevada corporation (the “Company”), and ____________ (“Indemnitee”).
Synergy CHC Corp. [●] Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • October 22nd, 2021 • Synergy CHC Corp. • Medicinal chemicals & botanical products • New York
The undersigned understands that you, as representative (the “Representative”), propose to enter into an underwriting agreement (the “Underwriting Agreement”) on behalf of the several Underwriters named in Schedule A to such agreement (collectively, the “Underwriters”), with Synergy CHC Corp, a Nevada corporation (the “Company”), providing for a public offering (the “Offering”) of shares (the “Shares”) of common stock of the Company (the “Common Stock”) pursuant to a Registration Statement on Form S-1 filed or to be filed with the Securities and Exchange Commission (the “SEC”). Capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Underwriting Agreement.
Settlement and Release AGREEMENTSettlement and Release Agreement • October 22nd, 2021 • Synergy CHC Corp. • Medicinal chemicals & botanical products • North Carolina
This Settlement and Release Agreement (“Agreement”) by and between Synergy CHC Corp., a Nevada corporation (“Releasor”), the former shareholders (the “Shareholders”) of Breakthrough Products, Inc., a Delaware corporation (the “Company”), URX ACQUISITION TRUST, a Delaware statutory trust (the “Trust”), on its own behalf and as the representative of the Shareholders, David T. Leyrer (“Leyrer”), Michael Valentino (“Valentino”), Ron Fugate (“Fugate”), and Randall Kaplan (“Kaplan”, and collectively with Leyrer, Valentino, Fugate, the “Former Directors”) is dated and effective as of the 17th day of December, 2015.
SECOND AMENDMENT TO AMENDED & RESTATED LOAN AGREEMENTLoan Agreement • October 22nd, 2021 • Synergy CHC Corp. • Medicinal chemicals & botanical products
The SECOND AMENDMENT to the AMENDED AND RESTATED LOAN AGREEMENT is entered into as of the 27th day of March 2019 (the “Second Amendment Agreement”),
AMENDMENT AND CONFIRMATION AGREEMENTAmendment and Confirmation Agreement • October 22nd, 2021 • Synergy CHC Corp. • Medicinal chemicals & botanical products • New York
THIS AGREEMENT, effective December 3rd, 2015, by and among KNIGHT THERAPEUTICS (BARBADOS) INC. (“Knight”), a corporation incorporated under the laws of Barbados, NOMAD CHOICE PTY LTD. (“Nomad”), a corporation formed under the laws of Australia, and SYNERGY CHC CORP. (“Synergy”), a corporation formed under the laws of the State of Nevada, and BREAKTHROUGH PRODUCTS, INC. (“Breakthrough”), a corporation formed under the laws of Delaware.
THIRD AMENDMENT AGREEMENT entered into as of the May 8, 2020 (the “Third Amendment”),Third Amendment Agreement • October 22nd, 2021 • Synergy CHC Corp. • Medicinal chemicals & botanical products • Quebec
WHEREAS the Borrower and the Lender are parties to that certain loan agreement made as of the 21st day of January, 2015, as amended by a first amending agreement dated November 12, 2015, as amended and restated as of the 9th day of August, 2017, as amended by a loan amendment agreement to the amended and restated loan agreement dated May 14, 2018 and as amended by a second amendment to the amended and restated loan agreement dated March 27, 2019 (such agreement, as amended, restated, amended and restated or otherwise modified from time to time as of the date hereof, the “Loan Agreement”);
LOAN AGREEMENT Dated as of January 22, 2015 between KNIGHT THERAPEUTICS (BARBADOS) INC. as Lender - and - SYNERGY STRIPS CORP. as BorrowerLoan Agreement • October 22nd, 2021 • Synergy CHC Corp. • Medicinal chemicals & botanical products • New York
THIS LOAN AGREEMENT is made with effect as of the 21st day of January, 2015, by and between SYNERGY STRIPS CORP., a corporation formed under the laws of the State of Nevada (the “Borrower’ ) and KNIGHT THERAPEUTICS (BARBADOS) INC., a corporation formed under the laws of Barbados, and one or more Persons to whom the foregoing or their permitted assigns may from time to time assign an interest in the Loan Documents (as defined below) (collectively, the “Lender”);
